RxDoctor Payments Data

Alexandra Price, DO

Internal Medicine · Summit, MSNPI 1033671557

Payments from drug & device makers

$909in general payments, 2019–2025

Across 42 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$326
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
  • Novo Nordisk$85
  • Pfizer$68
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$53
  • Lundbeck LLC$48
  • plus $237 from 10 others

What the payments were for

  • Food & beverage$909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$909 in reported general payments places this provider in the 60th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$127,790
Medicare patients
400
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$106,013
JardianceEmpagliflozin80$76,406
EliquisApixaban90$71,053
MounjaroTirzepatide31$43,228
JanuviaSitagliptin Phosphate35$28,803
XareltoRivaroxaban39$26,391
EntrestoSacubitril/Valsartan29$18,894
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,134
FarxigaDapagliflozin Propanediol24$13,576
Tresiba Flextouch U-200Insulin Degludec12$8,418
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$5,854
Tresiba Flextouch U-100Insulin Degludec11$4,565
SymbicortBudesonide/Formoterol Fumarate13$4,480
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,828
Albuterol Sulfate HfaAlbuterol Sulfate45$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$106,01382 claims
Boehringer IngelheimJardiance$17$76,40680 claims
PfizerEliquis$68$71,05390 claims
Lilly USA, LLCMounjaro$16$43,22831 claims
Johnson & JohnsonXarelto$37$26,39139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Summit

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →